RADIOCHEMICAL STABILITY DURING INFUSION OF I-131-LABELED METAIODOBENZYLGUANIDINE FOR THERAPEUTIC USE

被引：17

作者：

WAFELMAN, AR

HOEFNAGEL, CA

BEIJNEN, JH

机构：

[1] Department of Pharmacy, Slotervaart Hospital, Netherlands Cancer Institute, Amsterdam

[2] Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1993年 / 14卷 / 09期

关键词：

D O I：

10.1097/00006231-199309000-00014

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

I-131-labelled metaiodobenzylguanidine ([I-131]MIBG) is used both for diagnostic scintigraphy and for radionuclide therapy of neural crest derived tumours in particular neuroblastoma, malignant phaeochromocytoma and paraganglioma. This paper presents data on radiochemical stability during the infusion of 3.8, 5.7 and 7.7 GBq [I-131]MIBG in 100 ml infusion fluids for therapy. The period of investigation started at the moment of dilution of the thawed infusion concentrates (t = 0), which arrived in a frozen condition from the manufacturer, and ended at the termination of infusion (t = 7 h). In 7 h the percentage of free [I-131]iodide increased from 3.74 to 5.82, from 3.52 to 6.02 and from 3.72 to 6.40% in the 3.8, 5.7 and 7.7 GBq [I-131]MIBG infusion fluids, respectively. The 0-7 h increases of the different radioactive concentrations did not differ significantly. All the infusion fluids contained less than 7% free [I-131]iodide at the end of infusion (t = 7 h).

引用

页码：819 / 822

页数：4

共 25 条

[1]

Beierwaltes W.H., Applications of [13,I]MIBG, Nucl Med Biol, 14, pp. 183-189, (1987)

[2]

Hoefnagel C.A., Radionuclide therapy revisited, Eur J Nucl Med, 18, pp. 408-431, (1991)

[3]

Klingebiel T., Berthold F., Trcuner J., Schwabe D., Fischer M., Feine U., Maul F.D., Waters W., Wehinger H., Niethammer D., Metaiodobenzylguanidine (MIBG) in treatment of 47 patients with neuroblastoma: Results of the German neuroblastoma trial, Med Pediatr Oncol, 19, pp. 84-88, (1991)

[4]

Krempf M., Lumbroso J., Momex R., Brendel A.J., Wemeau J.L., Delisle M.J., Aubert G., Carpentier P., Fleury-Goyon M.C., Gibold C., Guyot M., Lahneche B., Marchandise X., Schlum- Berger M., Charbonnel B., Chatal J.F., Use of m- [131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma, J Clin Endocrinol Metab, 72, pp. 455-461, (1991)

[5]

Bayly R.J., Evans E.A., Stability and storage of compounds labelled with radioisotopes, J Label Comp, 2, pp. 1-34, (1966)

[6]

Wafelman A.R., Suchi R., Hoefnagel C.A., Beijnen J.H., Radiochemical purity of [131I]MIBG infusion fluids

[7]

a report from clinical practice, Eur J Nucl Med, 20, pp. 614-616, (1993)

[8]

Wafelman A.R., Hoefnagel C.A., Beijnen J.H., Chromatographic determination of the radiochemical purity of [l31I]MIBG infusion fluids: A comparison and discussion of the chromatographic characteristics using three different techniques, Appl Radiat Isot, 44, pp. 859-867, (1993)

[9]

Hoefnagel C.A., Hartog Jager Den F., Taal B.G., Abeling N., Engelsman H.E., The role of I-131-MIBG in the diagnosis and therapy of carcinoids, Eur J Nucl Med, 13, pp. 187-191, (1987)

[10]

Smets L.A., Loesberg C., Janssen M., Metwally E.A., Huis- Kamp R., Active uptake and extravesicular storage of m- iodobenzylguanidine in human neuroblastoma SK-N-SH cells, Cancer Res, 49, pp. 1-2941, (1989)

← 1 2 3 →